node-positive breast cancer
Oncology · 2005–2006
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| docetaxel Adjuvant treatment of node-positive breast cancer in combination with an anthracycline and cyclophosphamide. | Mar 2006 | Recommended with restriction | no section in document |
| paclitaxel Adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin hydrochloride and cyclophosphamide, removing the oestrogen receptor… | Mar 2006 | Recommended with restriction | no section in document |
| paclitaxel Adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin hydrochloride and cyclophosphamide, irrespective of oestrogen… | Mar 2006 | Recommended with restriction | no section in document |
| docetaxel Adjuvant treatment of operable node-positive breast cancer in combination with doxorubicin and cyclophosphamide. | Jul 2005 | Recommended | no section in document |
What the PBS pays
$21M in government benefit over 2024–25, across 148,113 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| paclitaxel | $16.4M |
| docetaxel | $4.9M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.